Brown Adipose Tissue Activity and Energy Metabolism in Cachexia
NCT ID: NCT02500004
Last Updated: 2018-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2015-06-30
2018-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Affecting BAT Activation in PET/CT
NCT05577299
Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT
NCT01000181
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
NCT06440122
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts
NCT06419244
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cachectic pancreatic cancer
Cachectic patients with pancreatic cancer
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
18F-FDG PET-MRI-imaging
BAT activity: 18F-FDG PET-MRI-imaging.
DXA scanning
Body composition: DXA scanning, D2O and MRI.
Abdominal subcutaneous adipose tissue biopsy
Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Blood sampling
Systemic inflammatory profile: blood sampling.
Indirect calorimetry
Resting metabolic rate: indirect calorimetry.
Accelerometry
Physical activity level: accelerometry.
Double-labeled water
Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Cachectic NSCLC
Cachectic patients with non-small cell lung cancer
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
18F-FDG PET-MRI-imaging
BAT activity: 18F-FDG PET-MRI-imaging.
DXA scanning
Body composition: DXA scanning, D2O and MRI.
Abdominal subcutaneous adipose tissue biopsy
Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Blood sampling
Systemic inflammatory profile: blood sampling.
Indirect calorimetry
Resting metabolic rate: indirect calorimetry.
Accelerometry
Physical activity level: accelerometry.
Double-labeled water
Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Cachectic COPD
Cachectic COPD patients.
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
18F-FDG PET-MRI-imaging
BAT activity: 18F-FDG PET-MRI-imaging.
DXA scanning
Body composition: DXA scanning, D2O and MRI.
Abdominal subcutaneous adipose tissue biopsy
Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Blood sampling
Systemic inflammatory profile: blood sampling.
Indirect calorimetry
Resting metabolic rate: indirect calorimetry.
Accelerometry
Physical activity level: accelerometry.
Double-labeled water
Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Non-cachectic COPD
Non-cachectic COPD patients.
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
18F-FDG PET-MRI-imaging
BAT activity: 18F-FDG PET-MRI-imaging.
DXA scanning
Body composition: DXA scanning, D2O and MRI.
Abdominal subcutaneous adipose tissue biopsy
Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Blood sampling
Systemic inflammatory profile: blood sampling.
Indirect calorimetry
Resting metabolic rate: indirect calorimetry.
Accelerometry
Physical activity level: accelerometry.
Double-labeled water
Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Healthy individuals
BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water.
18F-FDG PET-MRI-imaging
BAT activity: 18F-FDG PET-MRI-imaging.
DXA scanning
Body composition: DXA scanning, D2O and MRI.
Abdominal subcutaneous adipose tissue biopsy
Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Blood sampling
Systemic inflammatory profile: blood sampling.
Indirect calorimetry
Resting metabolic rate: indirect calorimetry.
Accelerometry
Physical activity level: accelerometry.
Double-labeled water
Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-FDG PET-MRI-imaging
BAT activity: 18F-FDG PET-MRI-imaging.
DXA scanning
Body composition: DXA scanning, D2O and MRI.
Abdominal subcutaneous adipose tissue biopsy
Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Blood sampling
Systemic inflammatory profile: blood sampling.
Indirect calorimetry
Resting metabolic rate: indirect calorimetry.
Accelerometry
Physical activity level: accelerometry.
Double-labeled water
Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The diagnostic criterion for cachexia is unintentional weight loss more than 5% over the past 6 months or more than 2% in individuals with a body-mass index \< 20 kg/m2 and muscle wasting assessed by DXA;
* Age ≥ 30 years;
* Gender: male and female;
* Caucasians.
Exclusion Criteria
* Patients with severe clotting disorder;
* Patients with an active second malignancy;
* Psychological unstable persons presumed unfit to perform the measurements, including claustrophobia;
* Persons unable to lie or sit still for 1-2 hours;
* Oxygen therapy;
* Pregnant subjects;Subjects unable to undergo MRI (e.g. pacemaker; neurostimulator; implantable cardioverter-defibrillator (ICD) or leads; Foley bladder catheter; medication pump; cochlear or hearing implant; tattoos or other items that cannot be removed and include metal parts (for instance from operations in the past); metal splinter in the eye; vascular clips; denture, which contains magnets);
* Subjects that received high doses of radiotherapeutic radiation of the neck and/or upper chest in their medical history;
* Persons that received cervical or thoracic sympathectomy or have a nerve dysfunction which is likely to influence sympathetic nerves;
* The use of medication that influences the sympathetic nerve system: ß-blockers, α-blockers, central anti-hypertensives, certain anti-depression drugs (MAO inhibitors, tricyclic anti-depressives), reserpine, cocaine, calciumblockers, labetalol, and certain tranquillizers (fenothiazines).
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maastricht University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Annemie Schols, PhD
Role: PRINCIPAL_INVESTIGATOR
Maastricht UMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maastricht UMC+
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sanders K, Klooster K, Vanfleteren LEGW, Plasqui G, Dingemans AM, Slebos DJ, Schols AMWJ. Effect of Bronchoscopic Lung Volume Reduction in Advanced Emphysema on Energy Balance Regulation. Respiration. 2021 Feb 5:1-8. doi: 10.1159/000511920. Online ahead of print.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL51402.068.14
Identifier Type: OTHER
Identifier Source: secondary_id
142071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.